Back to Search
Start Over
Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response
- Source :
- British journal of haematology. 185(4)
- Publication Year :
- 2018
- Subjects :
- Adult
Male
Dasatinib
Fusion Proteins, bcr-abl
Antineoplastic Agents
Drug Substitution
Myelogenous
Young Adult
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Medicine
Humans
Young adult
Survival analysis
Aged
business.industry
Hematology
Middle Aged
medicine.disease
Fusion protein
Survival Analysis
Leukemia
Pyrimidines
Molecular Response
Major Molecular Response
Cancer research
Imatinib Mesylate
Female
business
Subjects
Details
- ISSN :
- 13652141
- Volume :
- 185
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- British journal of haematology
- Accession number :
- edsair.doi.dedup.....5cb7b144efd3ad0e93c84ef4a9511116